E
MRSN

Ergoteles’s Mersana Therapeutics MRSN Stock Holding History

Ergoteles’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,286
Closed -$217K – 1722
2022
Q3 		$217K Buy
+1,286
New +$209K 0.01% 1139
2021
Q2 		– Sell
-544
Closed -$220K – 1617
2021
Q1 		$220K Buy
+544
New +$264K 0.01% 634

Other funds holding MRSN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ergoteles's MRSN Position: Q4 2022 in Review

Ergoteles sold out of Mersana Therapeutics (MRSN) in Q4 2022, closing a stake of 1,286 shares — an estimated $217K sold.

Ergoteles first reported a position in MRSN in Q1 2021 and held it in 2 quarters. The position peaked at $220K in Q1 2021. 152 funds tracked by Wall St. Rank hold MRSN as of Q4 2022.

  • Ergoteles reported no remaining Mersana Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ergoteles sold 1,286 Mersana Therapeutics shares in Q4 2022, an estimated $217K.
  • Ergoteles first reported a position in Mersana Therapeutics in Q1 2021 and held it in 2 quarters.
  • Ergoteles's Mersana Therapeutics position peaked at $220K in Q1 2021.
  • 152 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.